imatinib

(redirected from Gleevac)
Also found in: Medical.

i·mat·i·nib

 (ĭ-măt′ə-nĭb)
n.
A tyrosine kinase inhibitor, C29H31N7O, used in its mesylate form to treat certain types of leukemia and various other diseases.
References in periodicals archive ?
* Funding the work of Brian Druker, M.D., director, Knight Cancer Institute at Oregon Health & Science University, on Gleevac, an anti-cancer drug targeting leukemia; and,
(71.) Shamnad Basheer, First Mailbox Opposition (Gleevac) Decided in India, SPICY IP (Mar.
Gleevac, also called imatinib mesylate, is approved by the FDA to treat some types of leukemia and other forms of cancer.
Moreover, its overexpression is an independent prognostic marker specially for node positive patients.5 Some studies also suggest that Her2neu status predicts response to Adriamycin based adjuvant - chemotherapy and poor response to Tamoxifen even in the setting of positive Estrogen receptor expression.5 Gleevac targets BCR-ABL gene product, characteristic of Chronic Myeloid Leukaemia and is also effective in blocking the "Kinase Pocket" of the platelet derived growth factor receptor and C-Kit.
The recent patent clashes in the Indian courts on two anti-cancer drugs Gleevac and Erlontinib highlights the issue.
He was put on anti-cancer drug Gleevac and warned against starting a family.
The Swiss pharmaceutical company Novartis, which makes an anti-leukemia drug called Gleevac specifically targeting a particular form of cancer, has tested the new law, by seeking to overturn a local ruling that would have prevented Novartis from extending its patent over Gleevac, at a time when Indian generic drug makers want to enter the market.